CellGENTherapies
CellGENTherapies produces advanced gene-, cell- and tissue-therapeutic products (ATMPs) for early phase clinical trials according to good manufacturing principles (GMP).
We focus on the development and production of small batches of ATMPs (including personalized products) and prophylactic RNA vaccines for phase I studies helping UZ Gent, external clients and partners to move their research “from bench to bedside”.
News & Events
-
The new GMP facilities of Ghent University Hospital are entering the next phase.
In March this year, CellGENTherapies has announced their one full floor new GMP facility in the Nobel Building on Ghent University campus. This initiative is being funded by EFRO, FWO and the Ghent University Hospital. The team has worked hard to review the design plans of the cutting-edge cleanrooms with a focus on optimal processing…
-
CellGENTherapies playing a key role in innovative CAR-T cell manufacturing for children with acute lymphoblastic leukaemia.
Ghent University Hospital and its GMP facility CellGENTherapies, are partner in an ambitious, international (ATTRACT) study, called ARI-chALL, to investigate whether an innovative, academically developed CAR-T cell therapy can be used in children with acute lymphoblastic leukaemia during their first relapse. The new ARI-chALL study – which will take place in Belgium (Ghent), Spain, the…
CellGENTherapies is a member of
Vaxadvance is an initiative at Ghent University Hospital driven by four high level expertise centra who have strengthen their forces with the goal to accelerate breakthroughs in vaccine and therapeutic development.
- NanoMedicine Centre: nanoparticle-based formulation services
- the GMP unit CellGENTherapies: GMP production of ATMPs for early phase clinical trials
- the core ARTH Animal Facilities: lab animal-based preclinical research
- the Center for Vaccinology CEVAC: dedicated trial center Phase I – IV and Immuno-monitoring
With Vaxadvance, Ghent University Hospital continues playing a crucial role in driving the future of vaccine innovation.
Partners
Sponsors
